Stock Market & Financial Investment News

News Breaks September 24, 2012 10:04 EDT AZN AstraZeneca announces results from sub-analysis of PLATO AstraZeneca announced results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome. Results of this analysis suggest the overall findings from the PLATO study of a greater reduction in thrombotic cardiovascular events with BRILINTA tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age. These data are now published in the September print and online issues of Circulation: Cardiovascular Quality and Outcomes, and were presented at the American College of Cardiology 2011 meeting. News For AZN From The Last 14 Days Check below for free stories on AZN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 05:43 EDT AZN AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza Subscribe for More Information June 18, 2013 12:32 EDT AZN AstraZeneca CEO says turnaround to take three or four years, Reuters reports It will likely take three or four years for AstraZeneca's turnaround efforts to bear fruit, the company's CEO, Pascal Soriot, said today, according to Reuters. Reference Link 08:37 EDT AZN Drug companies turn to microchips to test medicines, WSJ reports Subscribe for More Information 07:22 EDT AZN Citigroup to host a conference Subscribe for More Information June 17, 2013 07:28 EDT AZN Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 09:03 EDT AZN Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. June 13, 2013 07:32 EDT AZN European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 13:15 EDT AZN Bristol-Myers, AstraZeneca issue statement on review of some therapies Subscribe for More Information 09:13 EDT AZN Amgen, AstraZeneca to advance brodalumab into Phase 3 studies Subscribe for More Information June 11, 2013 10:56 EDT AZN AstraZeneca to bid for Israeli biotech incubator, Globes reports Subscribe for More Information June 10, 2013 05:25 EDT AZN AstraZeneca acquires Pearl Therapeutics for up to $1.15B AstraZeneca announced that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Under the terms of the agreement, AstraZeneca will acquire 100% of Pearl's shares for initial consideration of $560M payable on completion. In addition, deferred consideration of up to $450M becomes payable if specified development and regulatory milestones in respect of any triple combination therapies and selected future products that AstraZeneca develops using Pearl's technology platform are achieved. Sales-related payments of up to a further $140M are payable if pre-agreed cumulative sales thresholds are exceeded resulting in a total potential acquisition cost of up to $1.15B. The proposed transaction is subject to customary regulatory approvals and is expected to close in the Q3 of 2013. The acquisition of Pearl Therapeutics has no impact on AstraZeneca's financial guidance for 2013. June 6, 2013 07:01 EDT AZN Isis Pharmaceuticals earns $6M payment from AstraZeneca Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.